home / stock / gnta / gnta news

GNTA News and Press, Genenta Science S.p.A. From 06/28/22

Stock Information
Company Name: Genenta Science S.p.A.
Stock Symbol: GNTA
Market: NASDAQ
Website: genenta.com
Menu
GNTA GNTA Quote GNTA Short GNTA News GNTA Articles GNTA Message Board
Get GNTA Alerts

News, Short Squeeze, Breakout and More Instantly...
GNTA - OAS, BRQS and BTCY among mid-day movers

Gainers: Endo International plc (ENDP) +95%. Agile Therapeutics (AGRX) +66%. Kezar Life Sciences (KZR) +53%. Decibel Therapeutics (DBTX) +25%. Ceragon Networks (CRNT) +23%. InflaRx (IFRX) +20%. Sutro Biopharma (STRO) +19%. Tyra Biosciences (TYRA) +17%. Oasis Petroleum (OAS) +16%. Biotricity (...
GNTA - Gene therapy developer Genenta stock tumbles 16%

Gene therapy developer Genenta Sciences (NASDAQ:GNTA), which went public in December, saw its stock tumble 16% on Tuesday. Shares of Genenta opened at $8.70, hitting a high of $9.33 early before slipping to a low of $5.33 in late morning. The stock recently changed hands at $6.69, down 16%, a...

GNTA - Genenta to Present at Upcoming Scientific Congresses ASGCT, BTM, ASCO and EHA

MILAN, Italy and NEW YORK, May 13, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, will be presenting at several upcoming scientific congresses in...

GNTA - Genenta Appoints Industry Veteran Tim Obara as Head of Business Development

MILAN, Italy and NEW YORK, May 09, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, announces the appointment of Tim Obara, a highly experienced co...
GNTA - Genenta Files Annual Report on Form 20-F for Fiscal Year 2021

MILAN, Italy and NEW YORK, May 04, 2022 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, today announced it filed its annual report on Form 20-F ...

GNTA - Genenta Progresses to Higher Dosing Cohort in Temferon(TM) Phase 1/2a Clinical Trial in Glioblastoma Multiforme

No dose limiting toxicity observed in previous three dose level cohorts Represents a 50% higher dose than highest prior level Update of guidance for trial MILAN, Italy and NEW YORK, May 04, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology compa...

GNTA - Genenta ASGCT Clinical Data Highlights Temferon(TM) Biological Effects in Glioblastoma

MILAN, Italy and NEW YORK, May 02, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, announces that preliminary findings from its Phase 1/2a of Temf...
GNTA - Genenta Announces Nomination of Mark A. Sirgo as Chair

35 years industry experience including as CEO and founder of public company Stephen Squinto steps down as Chair for new role MILAN, Italy and NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the developm...

GNTA - Genenta to Host Expert Fireside Chat on Immuno Gene & Cell Therapy for Treatment of Solid Tumors

MILAN, Italy and NEW YORK, April 20, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, announced it will hold a webinar entitled "Expert Perspective...

GNTA - Genenta Data Presentation at AACR to Describe On-Target Biological Activity of Temferon(TM) in Unmethylated Glioblastoma Multiforme

MILAN, Italy and NEW YORK, March 09, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, will present clinical data from its Phase 1/2a dose-escalatio...
Previous 10 Next 10